【瑞银升昭衍新药(06127.HK)目标价至14.3港元评级降至中性】金十数据4月3日讯，瑞银发表研究报告指，昭衍新药(06127.HK)去年业绩表现大致符合预期，收入按年跌15.1%，纯利按年跌81.3%，该行认为市场已大致上消化过去几季的复苏，这反映于集团去年次季新订量呈按季复苏，以及去年第二季至第四季非人类灵长类动物公允价值的稳定。然而，该行留意到，集团去年第四季新订单再次转弱，而今年首季中国生物制药资金疲软或是其一阻力。该行将公司今年、明年及2027年每股盈利预测下调1%、15%及26%，其目标价由12.6港元上调至14.3港元，其评级由买入降至中性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.